US2521311074
© BusinessWire
12.12.2025
DXCM
LISTED
NASDAQ
DexCom, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
DXCM
LISTED
NASDAQ
Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
News Preview
DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Sa...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
DXCM
LISTED
NASDAQ
DexCom, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DXCM
News Preview
LOS ANGELES, Dec. 4, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom " or "the Company") (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
26.11.2025
DXCM
LISTED
NASDAQ
DXCM INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of DexCom, Inc.
News Preview
The law firm of Kirby McInerney LLP reminds DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) investors of the December 26, 2025 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired DexCom securities between July 26, 2024 through September 17, 2025 (“the Class Period”).
Follow the link bel...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
25.11.2025
DXCM
LISTED
NASDAQ
Labaton Keller Sucharow LLP Announces Expanded Securities Class Action Lawsuit Filed Against DexCom, Inc. and Certain Executives
News Preview
Labaton Keller Sucharow LLP (“Labaton”) announces that, on November 25, 2025, it filed a securities class action lawsuit (the “Complaint”) on behalf of its client Boston Retirement System (“Boston”) against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) and certain DexCom officers (collectively, “Defendants”). The action, which is caption...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2025
DXCM
LISTED
NASDAQ
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
News Preview
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME provide...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2025
DXCM
LISTED
NASDAQ
Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes
News Preview
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged d...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
DXCM
LISTED
NASDAQ
Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
News Preview
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom’s World Diabetes Day campaign.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114585651/en/Dexcom’s Worl...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
DXCM
LISTED
NASDAQ
DexCom, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – DXCM
News Preview
The DJS Law Group reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of DXCM during the class p...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
DXCM
LISTED
NASDAQ
Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)
News Preview
Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l’assurance maladie du Québec (RAMQ) for eligible Québecers aged 18 and older living with type 2 diabetes who are treated with intensi...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2025
DXCM
LISTED
NASDAQ
DXCM Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc.
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
DXCM
LISTED
NASDAQ
Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
News Preview
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025.
Third Quarter 2025 Financial Highlights:
Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis.
U.S. revenue grew 21% and international revenue grew 22% on a report...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
30.10.2025
DXCM
LISTED
NASDAQ
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
DXCM
LISTED
NASDAQ
DCXM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. Investors
News Preview
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) securities during the period of July 26, 2024 through September 17, 2025, inclusive (“the Class Period”).
If you suffered a loss on your DexCom investments, you have u...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
DXCM
LISTED
NASDAQ
Rosen Law Firm Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class Period”). DexCom is a medical device company.
For more information, submit a fo...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
DXCM
LISTED
NASDAQ
Dexcom Appoints Euan Ashley to Board of Directors
News Preview
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025.
Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currentl...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
DXCM
LISTED
NASDAQ
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
If you currently own DexCom stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
DXCM
LISTED
NASDAQ
Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently w...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
DXCM
LISTED
NASDAQ
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025
News Preview
DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference.
This press release...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
DXCM
LISTED
NASDAQ
Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day
News Preview
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabetes Day (Nov. 14) and bey...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
DXCM
LISTED
NASDAQ
Dexcom Announces Upcoming Conference Presentations
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:
The 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025 at 2:15 pm (EDT)
The Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 2:00 pm (EDT)
Links to...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
DXCM
LISTED
NASDAQ
Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan
News Preview
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights:
Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis.
U.S. revenue grew 15% and international revenue grew 16% on a reported b...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
DXCM
LISTED
NASDAQ
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program
News Preview
Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the Ontario Drug Benefit (ODB) program for eligible Ontarians who manage their diabetes with insulin.*
This press release features multimedia. Vi...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
DXCM
LISTED
NASDAQ
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio
News Preview
DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the United States, following the feature’s launch on Dexcom G7 earlier this year.
This press release features multimedia. View the full rel...
Themefolio
Profiler
Peergroup
© BusinessWire
17.07.2025
DXCM
LISTED
NASDAQ
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews
News Preview
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
DXCM
LISTED
NASDAQ
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently w...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
DXCM
LISTED
NASDAQ
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025
News Preview
DexCom, Inc., the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 4...
Themefolio
Profiler
Peergroup
© BusinessWire
10.06.2025
DXCM
LISTED
NASDAQ
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
News Preview
Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain D...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
DXCM
LISTED
NASDAQ
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
News Preview
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer, which he has held since 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
DXCM
LISTED
NASDAQ
Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program
News Preview
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights:
Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis.
U.S. revenue grew 15% and international revenue grew 7% on a reported basis...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
DXCM
LISTED
NASDAQ
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U
News Preview
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its ros...
Themefolio
Profiler
Peergroup
© BusinessWire
19.04.2025
DXCM
LISTED
NASDAQ
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
News Preview
Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain De...
Themefolio
Profiler
Peergroup
© BusinessWire
10.04.2025
DXCM
LISTED
NASDAQ
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
News Preview
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%,3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to l...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
DXCM
LISTED
NASDAQ
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to review the company's first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcas...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
DXCM
LISTED
NASDAQ
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
News Preview
As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds this decision as a testament to the government’s commitment to improving diabete...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
DXCM
LISTED
NASDAQ
Dexcom Appoints Jon Coleman as Chief Commercial Officer
News Preview
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom’s global commercial organization, including global sales, marketing and customer experience.
Mr. Coleman joins Dexcom with more than 30 ye...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
DXCM
LISTED
NASDAQ
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
News Preview
DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany,...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
DXCM
LISTED
NASDAQ
Dexcom Appoints Renée Galá to Board of Directors
News Preview
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025.
Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
DXCM
LISTED
NASDAQ
Dexcom Announces Upcoming Conference Presentation
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tuesday, March 4th.
The live presentation is scheduled to begin at approximately 10:25 AM EST and will be concurrently webcast.
Links to the webcast will be available on the Dex...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
DXCM
LISTED
NASDAQ
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
News Preview
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024.
Fourth Quarter 2024 Financial Highlights:
Revenue grew 8% year-over-year to $1.114 billion on a reported basis and 8% year-over-year on an organic1 basis.
U.S. revenue grew 4% and international revenue grew 17...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
DXCM
LISTED
NASDAQ
Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold a conference call to review the company's fourth quarter and fiscal year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The con...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
DXCM
LISTED
NASDAQ
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
News Preview
DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. Internationa...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
DXCM
LISTED
NASDAQ
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025.
The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast.
Links to the webcast will be available on the Dexcom Investor Rela...
Themefolio
Profiler
Peergroup
© BusinessWire
21.12.2024
DXCM
LISTED
NASDAQ
DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into DexCom, Inc. (“DexCom” or the “Company”) (NasdaqGS: DXCM).
On July 25, 2024, the Company announced its financial results for the second quarter of fiscal 2024, d...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
DXCM
LISTED
NASDAQ
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
News Preview
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
DXCM
LISTED
NASDAQ
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
News Preview
Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older.
This press relea...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
DXCM
LISTED
NASDAQ
Dexcom and ŌURA Announce Strategic Partnership
News Preview
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, and ŌURA, maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. Combi...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
DXCM
LISTED
NASDAQ
Dexcom Helps People With Diabetes Take the First Step to Discover What They’re Made Of on World Diabetes Day
News Preview
This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first step to discover what they’re made of. This comes as global data1 shows nearly 70% of people with diabetes say they didn’t know where to begin their health journey when they were f...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
DXCM
LISTED
NASDAQ
Dexcom Reports Third Quarter 2024 Financial Results
News Preview
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024.
Third Quarter 2024 Financial Highlights:
Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis.
U.S. revenue declined 2% and international revenue grew 12% on a reported...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
DXCM
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faru...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
DXCM
LISTED
NASDAQ
RLF Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024. DexCom describes itself as an “international company that develops, manufactures, and distributes continuous glucose monitoring syst...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
DXCM
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DexCom, Inc. (DXCM)
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”).
If you are a shareho...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
DXCM
LISTED
NASDAQ
DXCM Deadline in 7 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”) The lead p...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
DXCM
LISTED
NASDAQ
Labaton Keller Sucharow LLP Announces Expanded Securities Class Action Lawsuit Filed Against DexCom, Inc. and Certain Executives
News Preview
Labaton Keller Sucharow LLP (“Labaton”) announces that, on October 8, 2024, it filed a securities class action lawsuit (the “Complaint”) on behalf of its clients Oakland County Employees’ Retirement System and Oakland County Voluntary Employees’ Beneficiary Association (the “Oakland County Funds”) against DexCom, Inc. (“DexCom” or the “Company”) (...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2024
DXCM
LISTED
NASDAQ
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against DexCom, Inc. (DXCM) – Deadline is October 21, 2024
News Preview
Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024 (the “Class Period”).
CLICK HERE TO JOIN THE CASE
If you are an investor in DexCom and have suffered losses, you may CLICK HERE to contact us. Yo...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
DXCM
LISTED
NASDAQ
Dexcom, Beyond Type 2 and Retta Establish National Glucose Awareness Week to Close the Glucose Knowledge Gap
News Preview
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in partnership with the nonprofit Beyond Type 2, are teaming up with author, producer and actress Retta to establish National Glucose Awareness Week from Sept. 23-29, 2024. National Glucose Awareness Week will help close the glucose k...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2024
DXCM
LISTED
NASDAQ
Dexcom Brings Mentorship to Centerfield, Welcomes New, Star Athletes to Its Ground-breaking NIL Program Dexcom U
News Preview
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company’s groundbreaking NIL (name, image, likeness) program exclusively for college athletes with diabetes.
This press release features multimedia. View the full...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2024
DXCM
LISTED
NASDAQ
Kirby McInerney LLP Notifies Dexcom Inc. (DXCM) Investors of Class Action Filing and Encourages Investors to Contact the Firm
News Preview
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Dexcom Inc. (“Dexcom” or the “Company”) (NASDAQ: DXCM) securities during the period of January 8, 2024 to July 25, 2024, inclusive (“the Class Period”)....
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
DXCM
LISTED
NASDAQ
Dexcom CGM Worn in Outer Space as Part of First-of-its-Kind Polaris Dawn Mission
News Preview
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better understand the effects of spaceflight o...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2024
DXCM
LISTED
NASDAQ
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violatio...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
